“Subsequent to the present acquisition, Richter now holds 100% of Gedeon Richter Rxmidas Joint Venture Co. Ltd., consequently it will be in full charge of its contraceptive and OTC business in China”, the announcement noted.

Richter considers the transaction an important step in underlining the company’s commitment to expanding its business operations in China, which the company dubbed one of the fastest growing pharmaceutical markets, the announcement added.